Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)Shiv Kumar Sarin, Imelda Maria Loho, Osamu Yokosuka et al.|Hepatology International|2020Cited by 295
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J. Sonneveld, Benjamin Maasoumy, Shao‐Ming Chiu et al.|Journal of Hepatology|2022Cited by 121
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J. Sonneveld, Benjamin Maasoumy, Jun Yong Park et al.|Clinical Gastroenterology and Hepatology|2020Cited by 103
Hepatitis B surface antigen, core‐related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuationApichat Kaewdech, Teerha Piratvisuth, Pisit Tangkijvanich et al.|Liver International|2020Cited by 46
Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific regionPojsakorn Danpanichkul, Apichat Kaewdech, Kanokphong Suparan et al.|Scientific Reports|2024Cited by 35